Lupus and cannabinoids: a complex disease with many unanswered questions

Lupus can affect many organs

Systemic lupus erythematosus (SLE) is a complex autoimmune condition. Its manifestations can involve skin, joints, blood, kidneys, nervous system, heart or lungs, sometimes in combination. Patients may experience quiet periods and flares, and the pattern of disease varies considerably between individuals. A change in pain is therefore only one part of the clinical picture.

Autoantibodies, immune complexes and interferon

Loss of immune tolerance allows autoreactive immune processes to develop. B cells may produce autoantibodies; immune complexes may form and contribute to tissue inflammation. T cells, dendritic cells, complement and type I interferon pathways are also important. Many patients show an elevated interferon-related gene signature, which is one reason modern lupus therapy targets specific immune pathways rather than an indiscriminate notion of “boosting immunity.”

Why the endocannabinoid system is being studied

CB2 receptors occur on B cells, T cells and other immune cells. Experimental work indicates that cannabinoid signaling can influence cytokines, lymphocyte behavior and several cell populations implicated in autoimmune disease. These observations establish a possible biological research route, not a demonstrated treatment for SLE.

Changes in 2-AG have been observed in people with SLE

The original Hebrew article discusses a human observational study reporting higher plasma levels of the endocannabinoid 2-AG and changes in enzymes involved in its metabolism. Within that study, higher 2-AG was associated with lower disease activity. An association cannot tell us whether the endocannabinoid system is counteracting inflammation or merely responding to illness; intervention studies would be needed.

Animal findings are complicated—and not always reassuring

Manipulating cannabinoid pathways or fatty-acid metabolism in lupus models can change immune signaling and antibodies, but effects depend on the model and intervention. A 2018 mouse study reported earlier development of proteinuria, a marker of kidney involvement, after CBD treatment. This does not prove CBD worsens lupus in humans. It does show why it would be unsafe to assume every cannabinoid is anti-inflammatory in every setting.

A selective CB2 drug did not deliver the hoped-for results

Lenabasum (formerly JBT-101) is a pharmacological CB2-directed compound, not ordinary cannabis oil. According to the trial discussed in the source, approximately twelve weeks of treatment did not show a convincing significant difference from placebo in pain or lupus disease-activity measures. A promising receptor target can fail to translate into effective therapy in people.

Could cannabinoids ease symptoms without altering lupus?

Some patients live with pain, stiffness or sleep problems that might respond to symptom-directed strategies. A cannabinoid effect on pain perception would not prove that autoantibodies have decreased, the kidneys are protected or lupus has entered remission. Research discussed in the original article does not establish cannabis as a disease-modifying SLE treatment.

Monitoring kidney and organ activity still matters

Lupus nephritis can develop without proportionate pain. Feeling better is not a substitute for disease monitoring. Depending on the individual, clinicians may assess urine findings, creatinine, complement levels, anti-dsDNA, blood counts and other indicators. A patient should not replace prescribed lupus treatment or follow-up with cannabis on the basis of symptomatic improvement.

Where the research may go next

Future work could examine selective receptor targeting, inflammatory biomarkers, immune-cell profiles, flare rates and organ-specific outcomes. Current reviews discussed in the Hebrew source emphasize that much mechanistic evidence is preclinical; human studies of cannabinoids in autoimmune conditions have largely focused on symptoms rather than proven changes in immune disease activity.

Bottom line

SLE is not a single symptom and cannabinoid biology is not a single mechanism. Endocannabinoid signaling is relevant to immune research, but both negative clinical results and potentially adverse animal findings warrant caution. Evidence presented here does not justify describing cannabis or CBD as a proven lupus treatment.

Read original Hebrew article ↗

Selected scientific sources

1. Endocannabinoid system in systemic lupus erythematosus: First evidence for a deranged 2-arachidonoylglycerol metabolism. Read source ↗
2. Cannabinoids in autoimmune diseases: mechanistic insights and translational challenges. 2026. Read source ↗
3. Clinical immunomodulatory effects of cannabinoids in autoimmune diseases in internal medicine. 2026. Read source ↗
4. Fatty acid amide metabolism in systemic lupus erythematosus: Evidence, mechanisms, and translational potential. 2026. Read source ↗
5. Cannabidiol Treatment in a Murine Model of Systemic Lupus Erythematosus Accelerates Proteinuria Development. 2018.
   Read source ↗
6. Cannabinoid Receptor 2 (CB2) in Macrophages: A Promising Clinical Target for Immune Disorders. 2025.
   Read source ↗
7. JBT-101 in Systemic Lupus Erythematosus (SLE), NCT03093402.
   Read source ↗